Overview

Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) From Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV)

Status:
Completed

Trial end date:
2020-09-04

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the safety and tolerability and virologic response of tenofovir alafenamide (TAF) in virologically suppressed chronic hepatitis B participants with renal and/or hepatic impairment.

Phase:

Phase 2

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Antiviral Agents
Tenofovir